myRAteam

Rinvoq (Upadacitinib) is a medication approved by the FDA for treating moderate to severe rheumatoid arthritis in adults who have not responded to Methotrexate. It is a Janus kinase inhibitor that works by blocking enzymes leading to inflammation. Rinvoq is taken once a day in extended-release tablet form. Common side Show Full Answer

Rinvoq (Upadacitinib) is a medication approved by the FDA for treating moderate to severe rheumatoid arthritis in adults who have not responded to Methotrexate. It is a Janus kinase inhibitor that works by blocking enzymes leading to inflammation. Rinvoq is taken once a day in extended-release tablet form. Common side effects include upper respiratory infections, fever, nausea, and cough. Serious side effects can include life-threatening infections, blood clots, liver problems, lymphomas, tuberculosis, and fetal harm in pregnant women. Always discuss with your doctor before starting any new medication.

 AI-generated responses are not a substitute for medical advice. These services are not intended to diagnose, treat, or cure any condition or disease. Always ask your doctor about specific health concerns.

FDA Approves Rinvoq, a New JAK Inhibitor, for Rheumatoid Arthritis

Rinvoq (Upadacitinib) for Rheumatoid Arthritis | myRAteam